Company’s multiple sclerosis Imotope™ shows promising preclinical efficacy and histology results while eliciting immune responses supporting the proposed mode of action and providing proof of concept
Liège, Belgium, September 12, 2019 – Imcyse, a clinical-stage company developing active and specific immunotherapeutics for the treatment and prevention of severe chronic diseases, today announces the presentation of a poster describing results obtained in the experimental autoimmune encephalomyelitis model (EAE), the widely used model for multiple sclerosis (MS).